

SEP 25 2008

DOCKET NO.: 48503-0005-00-US (AM100490)
Application No.: 09/991,089

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Jeffrey W. Pollard, *et al.*

Patent No.: 6,794,147

Application No.: 09/991,089

Issue Date: September 21, 2004

Filing Date: November 21, 2001

For: METHODS FOR IDENTIFYING CONTRACEPTIVE COMPOUNDS


REVOCATION OF POWER OF ATTORNEY
WITH NEW POWER OF ATTORNEY AND
CHANGE OF CORRESPONDENCE ADDRESS

I hereby revoke all previous powers of attorney given in the above-identified application.
I hereby appoint the practitioners associated with the Customer Number:

23973

Please change the correspondence address for the above-identified application to the
address associated with Customer Number 23973.

I am an authorized representative of one of the assignees of record of the entire interest in
the above-identified application. A Statement under 37 C.F.R. §3.73(b) is attached.

Signature			
Name	John L. Harb, Assistant Dean for Scientific Operations		
Date	9/29/08	Telephone	718-430-3357
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.			
<input checked="" type="checkbox"/> *Total of 1 forms are submitted.			

PHIP/711722.1



US006794147B1

(12) **United States Patent**
Pollard et al.

(10) Patent No.: **US 6,794,147 B1**
(45) Date of Patent: **Sep. 21, 2004**

(54) **METHODS FOR IDENTIFYING
CONTRACEPTIVE COMPOUNDS**

(75) Inventors: Jeffrey W. Pollard, New York, NY (US); Winfried Edelmann, Bronx, NY (US); Paula E. Cohen, Bronx, NY (US); Burkhard Kneitz, Wurzburg (DE); Panos Stevis, Glenmoore, PA (US); Raju S. Kucherlapati, Boston, MA (US)

(73) Assignees: Wyeth, Madison, NJ (US); Albert Einstein College of Medicine of Yeshiva University, Bronx, NY (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: 09/991,099

(22) Filed: Nov. 21, 2001

Related U.S. Application Data

(60) Provisional application No. 60/252,661, filed on Nov. 22, 2000.

(51) Int. Cl.⁷ G01N 33/53

(52) U.S. Cl. 435/7.1; 435/4; 435/6

(58) Field of Search 435/4, 6, 7.1

(56) **References Cited**

FOREIGN PATENT DOCUMENTS

WO WO 99/01550 A1 1/1999
WO WO 99/10369 A1 3/1999

OTHER PUBLICATIONS

Pochart et al. Journal of Biological Chemistry 272: 30345-30349, 1997.*

van Nocker et al. Molecular and Cellular Biology 16:6020-6028, 1996.*

Fu et al. Journal of Biological Chemistry 273: 1970-1981, 1998.*

Bocker T et al. hMSH5: a human MutS homologue that forms a novel heterodimer with hMSH4 and is expressed during spermatogenesis. Cancer Res. Feb. 15, 1999; 59(4):816-22.

Cohen PE et al. Regulation of meiotic recombination and prophase I progression in mammals. Bioessays. Nov. 2001; 23(11):996-1009.

Khazanehdari KA Borts RH. EXO1 and MSH4 differentially affect crossing-over and segregation. Chromosoma. 2000; 109(1-2):94-102.

Kneitz B et al. MutS homolog 4 localization to meiotic chromosomes is required for chromosome pairing during meiosis in male and female mice. Genes Dev. May 1, 2000; 14(9):1085-97.

Paquis-Fluckinger V et al. Cloning and expression analysis of a meiosis-specific MutS homolog: the human MSH4 gene. Genomics. Sep. 1, 1997; 44(2):188-94.

Winand NJ et al. Cloning and characterization of the human and Caenorhabditis elegans homologs of the Saccharomyces cerevisiae MSH5 gene. Genomics. Oct. 1, 1998; 53(1):69-80.

Zalevsky J et al. Crossing over during Caenorhabditis elegans meiosis requires a conserved MutS-based pathway that is partially dispensable in budding yeast. Genetics. Nov. 1999; 153(3):1271-83.

Gen Bank Accession AF104243, Homo sapiens meiosis-specific MutS homolog (MSH4) mRNA, complete cds. (Mar. 4, 1999).

Hollingsworth NM et al. MSH5, a novel MutS homolog, facilitates meiotic reciprocal recombination between homologs in Saccharomyces cerevisiae but not mismatch repair. Genes Dev. Jul. 15, 1995; 9(14):1728-39.

* cited by examiner

Primary Examiner—James Ketter

Assistant Examiner—David A. Lambertson

(74) *Attorney, Agent, or Firm*—Lahive & Cockfield LLP; Amy E. Mandragouras; Lisa M. DiRocco

(57) **ABSTRACT**

An animal, e.g., transgenic mouse, in which the MSH4 gene is misexpressed. The animal is useful for screening treatments for a number of conditions. Methods for identifying contraceptive agents are also described.

11 Claims, 7 Drawing Sheets